Literature DB >> 19652769

Withdrawal phenomena and dependence syndrome after the consumption of "spice gold".

Ulrich S Zimmermann1, Patricia R Winkelmann, Max Pilhatsch, Josef A Nees, Rainer Spanagel, Katja Schulz.   

Abstract

BACKGROUND: "Spice" and other herbal blends were marketed in Germany until January 2009 as substances purportedly exerting similar effects to cannabis, yet containing no cannabinoids. These products were recently forbidden in Germany under the provisions of the German Narcotics Law after they were found to contain undeclared, synthetic cannabinomimetic substances. The authors describe physical withdrawal phenomena and a dependence syndrome that developed after the consumption of "Spice." CASE PRESENTATION AND COURSE: A 20-year old patient reported that he had smoked "Spice Gold" daily for 8 months. He developed tolerance and rapidly increased the dose to 3 g per day. He felt a continuous desire for the drug and kept on using it despite the development of persistent cognitive impairment. His substance use led him to neglect his duties in his professional training position. Urinary drug screens were negative on admission to the hospital, as they were again on discharge. On hospital days 4-7, he developed inner unrest, drug craving, nocturnal nightmares, profuse sweating, nausea, tremor, and headache. His blood pressure was elevated for two days, with a maximal value of 180/90 mm Hg accompanied by a heart rate of 125/min. The patient stated that he had experienced a similar syndrome a few weeks earlier during a phase of abstinence owing to a short supply, and that it had quickly subsided after he had started consuming "Spice" once again.
CONCLUSIONS: The authors interpret the symptoms and signs described above as a dependence syndrome corresponding to the ICD-10 and DSM-IV criteria for this entity. The physical withdrawal syndrome closely resembles that seen in cannabis dependence. The authors postulate that the syndrome in the patient described was due to an admixture of synthetic cannabinomimetics such as JWH-018 and CP 47497 in "Spice Gold," in combination with the patient's daily consumption in very large amounts.

Entities:  

Keywords:  addictive behavior; designer drugs; drug abuse; drug-withdrawal therapy; pathogenesis of addiction

Mesh:

Substances:

Year:  2009        PMID: 19652769      PMCID: PMC2719097          DOI: 10.3238/arztebl.2009.0464

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  6 in total

1.  Bongs, a method of using cannabis linked to dependence.

Authors:  Henri Chabrol; Charlotte Roura; Jennifer Armitage
Journal:  Can J Psychiatry       Date:  2003-11       Impact factor: 4.356

Review 2.  Review of the validity and significance of cannabis withdrawal syndrome.

Authors:  Alan J Budney; John R Hughes; Brent A Moore; Ryan Vandrey
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

3.  'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?

Authors:  Volker Auwärter; Sebastian Dresen; Wolfgang Weinmann; Michael Müller; Michael Pütz; Nerea Ferreirós
Journal:  J Mass Spectrom       Date:  2009-05       Impact factor: 1.982

4.  [Dependency of non-benzodiazepine hypnotics. Two case reports].

Authors:  A Ströhle; I A Antonijevic; A Steiger; A Sonntag
Journal:  Nervenarzt       Date:  1999-01       Impact factor: 1.214

5.  Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops.

Authors:  F T A Pijlman; S M Rigter; J Hoek; H M J Goldschmidt; R J M Niesink
Journal:  Addict Biol       Date:  2005-06       Impact factor: 4.280

Review 6.  Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes.

Authors:  J W Huffman; L W Padgett
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

  6 in total
  73 in total

1.  Severe toxicity following synthetic cannabinoid ingestion.

Authors:  J Lapoint; L P James; C L Moran; L S Nelson; R S Hoffman; J H Moran
Journal:  Clin Toxicol (Phila)       Date:  2011-10       Impact factor: 4.467

2.  A survey study to characterize use of Spice products (synthetic cannabinoids).

Authors:  Ryan Vandrey; Kelly E Dunn; Jeannie A Fry; Elizabeth R Girling
Journal:  Drug Alcohol Depend       Date:  2011-08-10       Impact factor: 4.492

3.  Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice.

Authors:  Jason M Wiebelhaus; Justin L Poklis; Alphonse Poklis; Robert E Vann; Aron H Lichtman; Laura E Wise
Journal:  Drug Alcohol Depend       Date:  2012-07-07       Impact factor: 4.492

4.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

5.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

Review 6.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

7.  K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.

Authors:  Rita G McKeever; David Vearrier; Dorian Jacobs; Gregory LaSala; Jolene Okaneku; Michael I Greenberg
Journal:  J Med Toxicol       Date:  2015-03

Review 8.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

9.  Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.

Authors:  Kimberly L Samano; Justin L Poklis; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-05-09       Impact factor: 3.367

10.  Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Authors:  Maheswari Rajasekaran; Lisa K Brents; Lirit N Franks; Jeffery H Moran; Paul L Prather
Journal:  Toxicol Appl Pharmacol       Date:  2013-03-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.